254 related articles for article (PubMed ID: 24924179)
1. Oncolytic viruses for potential osteosarcoma therapy.
Hingorani P; Sampson V; Lettieri C; Kolb EA
Adv Exp Med Biol; 2014; 804():259-83. PubMed ID: 24924179
[TBL] [Abstract][Full Text] [Related]
2. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
3. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma.
Ketola A; Hinkkanen A; Yongabi F; Furu P; Määttä AM; Liimatainen T; Pirinen R; Björn M; Hakkarainen T; Mäkinen K; Wahlfors J; Pellinen R
Cancer Res; 2008 Oct; 68(20):8342-50. PubMed ID: 18922906
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Viruses and Their Potential as a Therapeutic Opportunity in Osteosarcoma.
Wedekind MF; Cripe TP
Adv Exp Med Biol; 2020; 1258():77-89. PubMed ID: 32767235
[TBL] [Abstract][Full Text] [Related]
6. The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.
Martínez-Vélez N; Xipell E; Vera B; Acanda de la Rocha A; Zalacain M; Marrodán L; Gonzalez-Huarriz M; Toledo G; Cascallo M; Alemany R; Patiño A; Alonso MM
Clin Cancer Res; 2016 May; 22(9):2217-25. PubMed ID: 26603261
[TBL] [Abstract][Full Text] [Related]
7. Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.
Cuddington B; Verschoor M; Mossman K
J Vis Exp; 2014 Nov; (93):e52232. PubMed ID: 25490047
[TBL] [Abstract][Full Text] [Related]
8. Going viral: a review of replication-selective oncolytic adenoviruses.
Larson C; Oronsky B; Scicinski J; Fanger GR; Stirn M; Oronsky A; Reid TR
Oncotarget; 2015 Aug; 6(24):19976-89. PubMed ID: 26280277
[TBL] [Abstract][Full Text] [Related]
9. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases.
Graat HC; van Beusechem VW; Schagen FH; Witlox MA; Kleinerman ES; Helder MN; Gerritsen WR; Kaspers GJ; Wuisman PI
Mol Cancer; 2008 Jan; 7():9. PubMed ID: 18215325
[TBL] [Abstract][Full Text] [Related]
10. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
11. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
13. Local Treatment of a Pediatric Osteosarcoma Model with a 4-1BBL Armed Oncolytic Adenovirus Results in an Antitumor Effect and Leads to Immune Memory.
Martinez-Velez N; Laspidea V; Zalacain M; Labiano S; García-Moure M; Puigdelloses M; Marrodan L; Gonzalez-Huarriz M; Herrador G; de la Nava D; Ausejo-Mauleon I; Fueyo J; Gomez-Manzano C; Patiño-García A; Alonso MM
Mol Cancer Ther; 2022 Mar; 21(3):471-480. PubMed ID: 34965961
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in cancer virotherapy: bringing the immune system into play.
Boisgerault N; Tangy F; Gregoire M
Immunotherapy; 2010 Mar; 2(2):185-99. PubMed ID: 20635927
[TBL] [Abstract][Full Text] [Related]
15. Evolving gene therapy approaches for osteosarcoma using viral vectors: review.
Witlox MA; Lamfers ML; Wuisman PI; Curiel DT; Siegal GP
Bone; 2007 Apr; 40(4):797-812. PubMed ID: 17189720
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
17. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
18. Questing for an optimal, universal viral agent for oncolytic virotherapy.
Paiva LR; Martins ML; Ferreira SC
Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Oct; 84(4 Pt 1):041918. PubMed ID: 22181186
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses for the treatment of neuroendocrine tumors.
Essand M; Leja J; Giandomenico V; Oberg KE
Horm Metab Res; 2011 Nov; 43(12):877-83. PubMed ID: 21626470
[TBL] [Abstract][Full Text] [Related]
20. Potent growth-inhibitory effect of TRAIL therapy mediated by double-regulated oncolytic adenovirus on osteosarcoma.
Li C; Cheng Q; Liu J; Wang B; Chen D; Liu Y
Mol Cell Biochem; 2012 May; 364(1-2):337-44. PubMed ID: 22354724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]